TuHURA Biosciences, Inc./NV
Close on Oct 19, 2026
- Market cap
- $113.86M
- P/E (TTM)
- –
- Dividend yield
- –
About TuHURA Biosciences
Pharmaceutical Preparations, SIC 2834
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology biopharmaceutical company focused on developing therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company’s pipeline utilizes three core technologies: the proprietary Immune Fx (IFx) platform, VISTA-inhibiting monoclonal antibodies, and Delta Opioid Receptor (DOR) targeting antibody-drug conjugates. Its lead candidate, IFx-2.0, is designed to stimulate innate immune responses against tumors and is in clinical testing as an adjunctive treatment for advanced Merkel cell carcinoma. Additional assets include TBS-2025 for acute myeloid leukemia and bi-functional antibody-drug conjugates targeting immunosuppressive myeloid-derived suppressor cells. Target end users are cancer patients with refractory disease or unmet therapeutic needs.
The company operates as a clinical-stage development enterprise without commercial sales channels or retail store networks. Its operations and clinical research initiatives are based in the United States, and it is incorporated under the laws of Nevada. TuHURA Biosciences does not state the location of its corporate headquarters in the provided text.
Summary of the business section of TuHURA Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TuHURA Biosciences, Inc./NV
- Founded
- 2009
- Headquarters
- Tampa, FL
- Address
- 10500 University Center Dr., Suite 110 33612
- Phone
- (813) 875-6600
- Website
- tuhurabio.com
- Employees
- 22, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Tampa, Florida
Stock & identifiers
- Ticker
- HURA
- Exchange
- Nasdaq
- IPO date
- Feb 22, 2013
- Shares outstanding
- 64M, Aug 11, 2026
- Public float
- $111.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-35 reverse, Nov 14, 2024; 1-for-35 reverse, Oct 18, 2024; 1-for-50 reverse, Nov 14, 2022; 1-for-50 reverse, Nov 10, 2022; 1-for-10 reverse, May 8, 2019; 1-for-10 reverse, May 7, 2019; 1-for-4 reverse, Sep 13, 2016
- SEC CIK
- 1498382
- CUSIP
- 898920103
- ISIN
- US8989201038
- LEI
- 549300N7OBMRNSOQC133
- EIN
- 99-0360497
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James A. Bianco | Chief Executive Officer, Director | 2,173,307 |
| Dan Dearborn | Chief Financial Officer | 0 |
| Robert E. Hoffman | Director | 68,902 |
| George K. Ng | Director | 0 |
| Alan List | Director | 0 |
| James S. J. Manuso | Director | 0 |
| Craig Tendler | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr Bianco | $3.99M | $1.78M | $1.83M | $0 | – |
| FY2024 Dr Bianco | $6.07M | $5.32M | $1.72M | $0 | – |
| FY2024 Robert Hoffman | $2.44M | $2.44M | $1.72M | $0 | – |
| FY2023 Dr Bianco | $1.21M | $1.21M | $325.03K | $4 | – |
| FY2023 Robert EHoffmann | $1.18M | $559.02K | $325.03K | $4 | – |
| FY2023 Robert Hoffman | $1.18M | $559.02K | $325.03K | $4 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 22 full-time employees and no part-time employees.”
Corporate history
Events identified from SEC filings